Royalty Pharma to Present at Upcoming Investor Conferences
Royalty Pharma to Present at Upcoming Investor Conferences
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry's leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma's current portfolio includes royalties on more than 35 commercial products, including Vertex's Trikafta, GSK's Trelegy, Roche's Evrysdi, Johnson & Johnson's Tremfya, Biogen's Tysabri and Spinraza, AbbVie and Johnson & Johnson's Imbruvica, Astellas and Pfizer's Xtandi, Novartis' Promacta, Pfizer's Nurtec ODT and Gilead's Trodelvy, and 15 development-stage product candidates. For more information, visit . NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of December:
紐約，2024年11月27日(GLOBE NEWSWIRE) -- royalty pharma股份有限公司（納斯達克：RPRX）今天宣佈，將參加以下即將舉行的投資者會議：
- 7th Annual Evercore ISI HealthCONx Conference on Tuesday, December 3 at 12:55 p.m. ET
- Citi's 2024 Global Healthcare Conference on Wednesday, December 4 at 1:45 p.m. ET
- 第七屆Evercore ISI HealthCONx會議，將於東部時間12月3日星期二下午12:55舉行。
- 花旗銀行的2024年全球醫療保健會議，將於東部時間12月4日星期三下午1:45舉行。
The webcasts will be accessible from Royalty Pharma's "Events" page at . Webcasts will also be archived for a minimum of thirty days.
網絡研討會將可從royalty pharma的「活動」頁面訪問。網絡研討會也將存檔至少三十天。
About Royalty Pharma
關於Royalty Pharma
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry's leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma's current portfolio includes royalties on more than 35 commercial products, including Vertex's Trikafta, GSK's Trelegy, Roche's Evrysdi, Johnson & Johnson's Tremfya, Biogen's Tysabri and Spinraza, AbbVie and Johnson & Johnson's Imbruvica, Astellas and Pfizer's Xtandi, Novartis' Promacta, Pfizer's Nurtec ODT and Gilead's Trodelvy, and 15 development-stage product candidates. For more information, visit .
成立於1996年，Royalty Pharma是生物製藥版權的最大買家，也是生物製藥行業創新的主要資助方，在學術機構、研究醫院和非盈利組織、中小型生物技術公司和全球領先製藥公司之間與創新者合作。Royalty Pharma已經建立起一系列版權組合，使其有資格根據行業領先治療方案的銷售額直接獲得支付。Royalty Pharma通過直接和間接兩種方式資助生物製藥行業的創新 - 直接方式是與公司合作共同資助臨床試驗的後期階段和新產品推出，以換取未來的版稅，間接方式是從原始創新者那裏收購現有的版稅。Royalty Pharma目前的投資組合包括超過35種商業產品的版權，包括vertex的Trikafta，GSK的Trelegy，Roche的Evrysdi，強生的Tremfya，Biogen的Tysabri和Spinraza，艾伯維和強生的Imbruvica，愛力斯達和輝瑞的Xtandi，諾華的Promacta，輝瑞的Nurtec ODt和吉利德的Trodelvy，以及15個處於開發階段的產品候選。欲獲取更多信息，請訪問。
Royalty Pharma Investor Relations and Communications
Royalty Pharma投資者關係與溝通
+1 (212) 883-6772
ir@royaltypharma.com
+1 (212) 883-6772
ir@royaltypharma.com
譯文內容由第三人軟體翻譯。
